<doc>
  <docmeta id="113hr1429ih">
    <bill congress="113" type="hr" number="1429" version="ih"/>
    <revision size="3110" annotations="0" id="4" commit-time="2013-04-16T20:17:27+00:00" committer="favila" doc="113hr1429ih/4.xml" status="complete">
      <description/>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H090659FA429C4A8CAFAC53764E8F5CEB" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 1429 IH: Scleroderma Research and Awareness Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-04-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1429</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130409">April 9, 2013</action-date>
			<action-desc>
        <sponsor name-id="C001036">Mrs. Capps</sponsor> (for
			 herself and <cosponsor name-id="K000210">Mr. King of New York</cosponsor>)
			 introduced the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To expand the research and awareness activities of the
		  National Institute of Arthritis and Musculoskeletal and Skin Diseases and the
		  Centers for Disease Control and Prevention with respect to scleroderma, and for
		  other purposes.</official-title>
	</form>
	<legis-body id="HDD2F09916BF544F8B9172A25B02FC87E" style="OLC">
		<section id="HC356773184EA40C2ABAF64DD125FF496" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Scleroderma Research and Awareness Act
			 of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H471B6005B4FF4EC195BA3EB11775A10E">
      <enum>2.</enum>
      <header>National
			 institute of arthritis and musculoskeletal and skin diseases; scleroderma
			 research expansion</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:IV/pt:B">Part B of title IV of the Public Health
			 Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/284/etseq">42 U.S.C. 284 et seq.</cato:entity-ref>)</cato:entity> is amended by adding at the end the
			 following:</text>
			<quoted-block display-inline="no-display-inline" id="HB22ED7A7578E4E9FBB7C254586E66CA0" style="OLC">
				<section id="H25B130B434D34E3287B3706212359A29">
          <enum>409K.</enum>
          <header>Scleroderma
				research</header>
          <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of NIH</cato:entity-ref>
				may expand, intensify, and coordinate the activities of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes
				of Health</cato:entity-ref> with respect to scleroderma, with particular emphasis on the
				following:</text>
					<paragraph id="H4EB4D1A0CAFF41DE92DAA0BD20ACC5C8">
            <enum>(1)</enum>
            <text>Research focused
				on the etiology of scleroderma and the development of new treatment
				options.</text>
					</paragraph>
          <paragraph id="H575031166F6642049C01EDF3B6C46AE3">
            <enum>(2)</enum>
            <text>Clinical research
				to evaluate new treatments options.</text>
					</paragraph>
          <paragraph id="H6AF6D888F36247EFA89713367A424487">
            <enum>(3)</enum>
            <text>Basic research on
				the relationship between scleroderma and secondary conditions such as pulmonary
				hypertension, gastroparesis, Raynaud's phenomenon, Sjögren's Syndrome, and
				other diseases as determined by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director</cato:entity-ref>.</text>
					</paragraph>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H587120B818284F259EA669F834E67B8D">
      <enum>3.</enum>
      <header>Promoting public
			 awareness of scleroderma</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:III/pt:P">Part
			 P of title III of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/280g">
            <cato:entity-ref entity-type="uscode" value="usc/42/280g/etseq">42 U.S.C. 280g et seq.</cato:entity-ref>
          </external-xref>)</cato:entity> is
			 amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H05CFAF51CC2940CC84959A6101AFB4EF" style="OLC">
				<section id="H8E830345A8054D6E9673F2E7E5676E29">
          <enum>399V–6.</enum>
          <header>Promoting
				public awareness of scleroderma</header>
          <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may carry out an educational
				campaign to increase public awareness of scleroderma. Print, video, and
				Web-based materials distributed through this campaign may include—</text>
					<paragraph id="H93DF976244AE40E78E9C7AB696E2AE9C">
            <enum>(1)</enum>
            <text>basic information
				on scleroderma and its symptoms; and</text>
					</paragraph>
          <paragraph id="H29BC20035BB34BBC8EB894BB1874A7D6">
            <enum>(2)</enum>
            <text>information
				on—</text>
						<subparagraph id="H1DD3B4BFBADA44E888EDEC404D63EA86">
              <enum>(A)</enum>
              <text>the incidence and
				prevalence of scleroderma;</text>
						</subparagraph>
            <subparagraph id="H1F8D2618130246009F4B1A16F8050A61">
              <enum>(B)</enum>
              <text>diseases and
				conditions affiliated with scleroderma; or</text>
						</subparagraph>
            <subparagraph id="HA2A7AC414C7E4F36A22662BE38E87170">
              <enum>(C)</enum>
              <text>the importance of
				early diagnosis and treatment of
				scleroderma.</text>
						</subparagraph>
          </paragraph>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
  </legis-body>
</bill>
</doc>